Ultragenyx’s $203 Million Voucher Sale Adds a Non-Dilutive Cash Catalyst
Ultragenyx’s planned $203 million FDA voucher sale gives $RARE a potential cash catalyst without issuing new shares.
Ultragenyx’s $203 Million Voucher Sale Sets a New Cash Benchmark for Biotech
Ultragenyx’s agreed $203 million voucher sale could strengthen its balance sheet and give biotech in…
Galderma’s $1.5 Billion ZO Skin Health Deal Signals More Consolidation in Dermatology
Galderma’s $1.5 billion cash purchase of ZO Skin Health highlights continued consolidation across de…
Vaxcyte Raises $1.15 Billion to Advance VAX-31 as PCVX Shares Surge
Vaxcyte’s $1.15 billion public offering strengthens funding for VAX-31 while putting shareholder dil…
UnitedHealth Raises 2026 Earnings Outlook as Medical-Cost Management Supports Q3 Beat
UnitedHealth raised its 2026 adjusted earnings outlook to at least $20.50 per share after a Q3 beat,…
Bristol Myers Squibb Gains on Dual Phase 3 Wins and CAMZYOS Label Expansion
Bristol Myers Squibb shares gained on dual Phase 3 wins, CAMZYOS expansion and fresh analyst comment…
Bristol Myers Squibb Stock Jumps 6.5% on Dual Phase 3 Wins and Expanded CAMZYOS Approval
Bristol Myers Squibb shares jumped 6.5% after two positive Phase 3 updates and expanded FDA approval…
Syndax Stock Drops 12.2% After Axatilimab Trial Miss Raises Biotech Risk Concerns
Syndax shares fell 12.2% to $14.54 in pre-open trading after its MAXPIRe Phase 2 axatilimab trial di…
UnitedHealth Raises 2026 Profit Outlook as Q3 Beat Overcomes Medical-Cost Pressure
UnitedHealth topped Q3 estimates and raised its 2026 profit outlook, offering a closely watched sign…
STERIS to Buy Xodus Medical for $2.1 Billion in Surgical-Device Expansion
STERIS’s $2.1 billion purchase of Xodus Medical would broaden its surgical-device portfolio and unde…